EB病毒阳性弥漫大B细胞淋巴瘤的治疗

Treatment of EB virus positive diffuse large B cell lymphoma

EB病毒(EBV)阳性弥漫大B细胞淋巴瘤(DLBCL)是与慢性EBV感染相关的一类罕见的B细胞淋巴瘤。主要为活化B细胞亚型,具有侵袭性,对联合化疗的反应较EBV阴性患者差,预后不良。随着对EBV阳性DLBCL发病机制、生物学特征的研究不断深入,新型治疗策略不断出现,如抗病毒治疗、单克隆抗体、信号通路抑制剂以及包括细胞免疫疗法和免疫检查点抑制剂在内的免疫疗法,这些新的治疗策略能够提高疗效,并减少不良反应的发生。

Epstein-Barr virus(EBV)positive diffuse large B cell lymphoma(DLBCL)is a rare type of B cell lymphoma associated with chronic EBV infection.The main subtype is activated B cell-like and it's invasive.The response to combined chemotherapy is worse than that of EBV negative patients,and the prognosis is poor.As the researches on pathogenesis and biological characteristics of EBV positive DLBCL deepen,new therapeutic strategies are emerging,such as antiviral therapy,monoclonal antibody,inhibitors of signaling pathway and immunotherapy including cellular immunotherapy and immune checkpoint inhibitor.These new therapeutic strategies can improve the efficacy and reduce the occurrence of adverse reactions.